Esophageal heterotopic tissue
Bergmann et al. (1958) first reported this type of malformation, also known as solid intramural tracheolbronchial rests in the esophagus or choristomas. Both the esophagus and the trachea develop from the embryonic foregut. In the third week of the embryo, the two are a common tubular organ. During the separation of the trachea and esophagus in the sixth week, tracheal cartilage is lost in the esophageal wall. The esophageal wall contains mucous glands, which mostly occur in the lower esophagus.
-
Site of disease:
esophagus -
Infectious :
Not contagious -
Frequent population:
Newborns (less than one month old) Infants (2-... -
Related symptoms:
Difficulty swallowing choking difficulty breathing nausea difficulty breathing -
Concurrent disease:
Related Drugs
Enteral Nutrition Suspension (TPF)
Indication: This product is suitable for patients who have gastrointestinal function or partial gastrointestinal function but cannot or are unwilling to eat enough regular food to meet the body's nutritional needs and should undergo enteral nutrition therapy. It is mainly used for: 1. Anorexia and its related diseases - loss of appetite caused by metabolic stress, such as trauma or burns - neurological/psychiatric diseases or injuries - impaired consciousness - cachexia of heart/lung diseases - cancer cachexia and the late stage of cancer treatment - HIV infection/AIDS; 2. Mechanical gastrointestinal dysfunction - maxillofacial injuries - head and neck cancer - swallowing disorders - upper gastrointestinal obstruction, such as esophageal stenosis; 3. Critical diseases - large-area burns - trauma - sepsis - recovery period after major surgery; 4. Preoperative feeding of malnourished patients; 5. This product can be used for diabetic patients.
Enteral Nutrition Suspension (TPF)
Indication: This product is suitable for patients who have gastrointestinal function or partial gastrointestinal function but cannot or are unwilling to eat enough regular food to meet the body's nutritional needs and should undergo enteral nutrition therapy. It is mainly used for: 1. Anorexia and its related diseases - loss of appetite caused by metabolic stress, such as trauma or burns - neurological/psychiatric diseases or injuries - impaired consciousness - cachexia of heart/lung diseases - cancer cachexia and the late stage of cancer treatment - HIV infection/AIDS; 2. Mechanical gastrointestinal dysfunction - maxillofacial injuries - head and neck cancer - swallowing disorders - upper gastrointestinal obstruction, such as esophageal stenosis; 3. Critical diseases - large-area burns - trauma - sepsis - recovery period after major surgery; 4. Preoperative feeding of malnourished patients; 5. This product can be used for diabetic patients.
Related Ingredients
-
Water list
7732-18-5 -
Maltodextrin list
9050-36-6 -
Casein list
9000-71-9 -
PASSION FLOWER OIL list
68956-68-3